Bergeron M G, Marois Y
Kidney Int. 1986 Oct;30(4):481-7. doi: 10.1038/ki.1986.211.
The importance of high intrarenal levels of gentamicin on the outcome of experimental pyelonephritis was studied in rats receiving either a short course (three days) of gentamicin (G) alone or combined with a longer course (14 days) of ampicillin (A), cephalothin (C), or trimethoprim (T), or two weeks of therapy with ampicillin, cephalothin, trimethoprim and gentamicin given alone. While ampicillin, cephalothin and trimethoprim were undetectable in the medulla within six hours of cessation of therapy, gentamicin was still detectable in levels six folds above the MIC up to six months after treatment had ceased. Six months after the end of treatment, the percentage of sterile left kidneys in animals treated with ampicillin (50%), cephalothin (15%), trimethoprim (20%) was lower than the percentage of animals receiving 14 days of gentamicin (100%), or the combinations AG:89%, CG:67% and TG:60%, P less than 0.01. Following three days of gentamicin, 50% of the left kidneys were sterilized. When compared to ampicillin, cephalothin or trimethoprim alone, combined therapies significantly reduced the number of CFU in the kidneys P less than 0.01. These combinations were almost as effective as two weeks of therapy with gentamicin. Short-term therapy (three days) with an aminoglycoside which concentrates in the renal parenchyma, combined with an antibiotic which will accumulate in other parts of the nephron, may result in "pharmacological synergy". This new approach to therapy of pyelonephritis may be promising.
在接受短期(三天)单独使用庆大霉素(G)或与较长疗程(14天)的氨苄西林(A)、头孢噻吩(C)或甲氧苄啶(T)联合使用,或单独使用氨苄西林、头孢噻吩、甲氧苄啶和庆大霉素进行两周治疗的大鼠中,研究了肾内庆大霉素高浓度对实验性肾盂肾炎结果的影响。虽然在治疗停止后6小时内,髓质中无法检测到氨苄西林、头孢噻吩和甲氧苄啶,但在治疗停止后长达6个月的时间里,仍可检测到庆大霉素的水平比最低抑菌浓度(MIC)高6倍。治疗结束6个月后,接受氨苄西林(50%)、头孢噻吩(15%)、甲氧苄啶(20%)治疗的动物左肾无菌的百分比低于接受14天庆大霉素治疗的动物(100%),或AG组合(89%)、CG组合(67%)和TG组合(60%),P小于0.01。在使用庆大霉素三天后,50%的左肾被灭菌。与单独使用氨苄西林、头孢噻吩或甲氧苄啶相比,联合治疗显著降低了肾脏中的菌落形成单位(CFU)数量,P小于0.01。这些联合治疗几乎与使用庆大霉素进行两周治疗一样有效。短期(三天)使用一种集中在肾实质中的氨基糖苷类药物,再联合一种会在肾单位其他部位蓄积的抗生素,可能会产生“药理协同作用”。这种治疗肾盂肾炎的新方法可能很有前景。